Cargando…
Update on Salvage Options in Relapsed/Refractory Hodgkin Lymphoma after Autotransplant
Despite a high clinical success, relapse in Hodgkin lymphoma occurs in 10–30% of cases and 5–10% patients are nonresponsive to initial chemotherapy. The standard management of these patients includes high-dose chemotherapy followed by autologous stem cell transplant. However, 50% of patients ultimat...
Autores principales: | Iqbal, Nida, Kumar, Lalit, Iqbal, Naveed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003874/ https://www.ncbi.nlm.nih.gov/pubmed/25006506 http://dx.doi.org/10.1155/2014/605691 |
Ejemplares similares
-
Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
por: Fedele, Roberta, et al.
Publicado: (2015) -
Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma: So Many Options, How to Choose?
por: Takiar, Radhika, et al.
Publicado: (2022) -
Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020) -
ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
por: Choi, Chul Won, et al.
Publicado: (2002) -
Immunotoxin – a new treatment option in patients with relapsed and refractory Hodgkin lymphoma
por: Novakovic, Barbara Jezersek
Publicado: (2015)